Salvia divinorum: From Mazatec medicinal and hallucinogenic plant to emerging recreational drug

Human Psychopharmacology

Volumn 28, Issue 5, 2013, Pages 403-412

  Zawilska, Jolanta B ^a   Wojcieszak, Jakub ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

hallucinogenic drugs; herbal highs; kappa opioid receptor; Salvia divinorum; salvinorin A

Indexed keywords

CANNABINOID RECEPTOR; CARBON 11; CHOLINERGIC RECEPTOR; COCAINE; DOPAMINE; DYNORPHIN A; ENADOLINE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; KETAMINE; LYSERGIDE; MESCALINE; MU OPIATE RECEPTOR; N,N DIMETHYLTRYPTAMINE; PLANT MEDICINAL PRODUCT; PSILOCYBINE; PSYCHEDELIC AGENT; RECREATIONAL DRUG; SALVINORIN A; SALVINORIN B; SALVINORIN C; SALVINORIN D; SALVINORIN E; SALVINORIN F; SALVINORIN G; SALVINORIN H; SALVINORIN I; SEROTONIN; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CHEMICAL COMPOSITION; CHEMICAL STRUCTURE; COGNITION; CONFUSION; DEPRESSION; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SEEKING BEHAVIOR; GLUCOSE METABOLISM; HALLUCINATION; HOT FLUSH; HUMAN; HYPOTHALAMUS; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MEDICINAL PLANT; MENTAL DISEASE; MENTAL PATIENT; MOTIVATION; MUSCLE RELAXATION; NONHUMAN; PHYTOCHEMISTRY; POSITRON EMISSION TOMOGRAPHY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROTEIN STABILITY; PSYCHOSIS; RHESUS MONKEY; SALVIA; SALVIA DIVINORUM; SEDATION; SINGLE DRUG DOSE; SMOKE; SYNAPTOSOME; TACHYCARDIA;

HALLUCINOGENIC DRUGS; HERBAL HIGHS; KAPPA OPIOID RECEPTOR; SALVIA DIVINORUM; SALVINORIN A;

ANIMALS; DITERPENES, CLERODANE; HALLUCINOGENS; HUMANS; MEDICINE, TRADITIONAL; MEXICO; SALVIA; STREET DRUGS;

EID: 84884146936     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2304     Document Type: Article

References (62)

1. Addy PH,. 2012. Acute and post-acute behavioral and psychological effects of salvinorin A in humans. Psychopharmacol 220: 195-204.
2. Albertson DN, Grubbs LE,. 2009. Subjective effects of Salvia divinorum: LSD- or marijuana-like?. J Psychoactive Drugs 41: 213-217.
3. Ansonoff MA, Zhang J, Czyzyk T, et al,. 2006. Antinociceptive and hypothermic effects of salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice. J Pharmacol Exp Ther 318: 641-648.
4. Baggott MJ, Erowid E, Erowid F, Galloway GP, Mendelson J,. 2010. Use patterns and self-reported effects of Salvia divinorum: an Internet-based survey. Drug Alcohol Depend 111: 250-256.
5. Barnes BB, Snow NH,. 2012. Analysis of salvinorin A in plants, water, and urine using solid-phase microextraction-comprehensive two-dimensional gas chromatography-time of flight mass spectrometry. J Chromatogr A 1226: 110-115.
6. Baker LE, Panos JJ, Killinger B, et al,. 2009. Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats. Psychopharmacology 203: 203-211.
7. Braida D, Donzell A, Martucci R, Sala M,. 2011. Learning and memory impairment induced by salvinorin A, the principal ingredient of Salvia divinorum, in Wistar rats. Int J Toxicol 30: 650-661.
8. Butelman ER, Prisinzano TE, Deng H, Rus S, Kreek MJ,. 2009. Unconditioned behavioral effects of the powerful κ-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid. J Pharmacol Exp Ther 328: 588-597.
9. Butelman ER, Rus S, Prisinzano TE, Kreek MJ,. 2010. The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects. Psychopharmacology (Berl) 210: 253-262.
10. Carlezon WA Jr, Béguin C, DiNieri JA, et al,. 2006. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316: 440-447.
11. Casselman I, Heinrich M,. 2011. Novel use of Salvia divinorum: unobtrusive observation using YouTube™. J Ethnopharmacol 138: 662-667.
12. Chartoff EH, Potter D, Damez-Werno D, Cohen BM, Carlezon WA Jr., 2008. Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats. Neuropsychopharmacology 33: 2676-2687.
13. Cunningham CW, Rothman RB, Prisinzano TE,. 2011. Neuropharmacology of the naturally occurring κ-opioid hallucinogen salvinorin A. Pharmacol Rev 63: 316-347.
14. Currie CL,. 2013. Epidemiology of adolescent Salvia divinorum use in Canada. Drug Alcohol Depend 128: 166-170.
15. Deluca P, Davey Z, Corazza O, et al,. 2012. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog Neuropsychopharmacol Biol Psychiatry 39: 221-226.
16. Fantegrossi WE, Kugle KM, Valdes LJ 3rd, Koreeda M, Woods JH,. 2005. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. Behav Pharmacol 16: 627-633.
17. Ford JA, Watkins WC, Blumenstein L,. 2011. Correlates of Salvia divinorum use in a national sample: findings from the 2009 National Survey on Drug Use and Health. Add Behav 36: 1032-1037.
18. Giroud C, Felber F, Augsburger M, Horisberger B, Rivier L, Mangin P,. 2000. Salvia divinorum: a hallucinogenic mint which might become a new recreational drug in Switzerland. Forensic Sci Int 112: 143-150.
19. González D, Riba J, Bouso JC, Gõmez-Jarabo G, Barbanoj MJ,. 2006. Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend 85: 157-162.
20. Grilli M, Neri E, Zappettini S, et al,. 2009. Salvinorin A exerts opposite presynaptic controls on neurotransmitter exocytosis from mouse brain nerve terminals. Neuropsychopharmacology 57: 523-530.
21. Gruber JW, Siebert DJ, Der Marderosian AH, Hock RS,. 1999. High performance liquid chromatographic quantification of salvinorin A from tissues of Salvia divinorum epling and játiva-m. Phytochem Anal 10: 22-25.
22. Halpern JH, Pope HG Jr., 2001. Hallucinogens on the Internet: a vast new source of underground drug information. Am J Psychiatry 158: 481-483.
23. Hanes KR,. 2001. Antidepressant effects of the herb Salvia divinorum: a case report. J Clin Psychopharmacol 21: 634-635.
24. Harden MT, Smith SE, Niehoff JA, McCurdy CR, Taylor GT,. 2012. Antidepressive effects of the κ-opioid receptor agonist salvinorin A in a rat model of anhedonia. Behav Pharmacol 23: 710-715.
25. Hooker JM, Xu Y, Schiffer W, Shea C, Carter P, Fowler JS,. 2008. Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset, short duration of effects in humans. NeuroImage 41: 1044-1050.
26. Hooker JM, Patel V, Kothari S, Schiffer WK,. 2009. Metabolic changes in the rodent brain after acute administration of salvinorin A. Mol Imaging Biol 11: 137-143.
27. Hoover V, Marlowe DB, Patapis NS, Festinger DS, Forman RF,. 2008. Internet access to Salvia divinorum: implications for policy, prevention, and treatment. J Subst Abuse Treat 35: 22-27.
28. Kelly BC,. 2011. Legally tripping: a qualitative profile of Salvia divinorum use among young adults. J Psychoactive Drugs 32: 46-54.
29. Khey DH, Miller BL, Griffin OH,. 2008. Salvia divinorum use among a college student sample. J Drug Education 38: 297-306.
30. Killinger BA, Peet MM, Baker LE,. 2010. Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague-Dawley rats. Pharmacol Biochem Behav 96: 260-265.
31. Lange JE, Reed MB, Croff JM, Clapp JD,. 2008. College student use of Salvia divinorum. Drug Alcohol Depend 94: 263-266.
32. Lange JE, Daniel J, Homer K, Reed MB, Clapp JD,. 2010. Salvia divinorum: effects and use among YouTube users. Drug Alcohol Depend 108: 138-140.
33. MacLean KA, Johnson MW, Reissig CJ, Prisinzano TE, Griffiths RR,. 2013. Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacol (Berl) 226: 38-92.
34. Medana C, Massolino C, Pazzi M, Baiocchi C,. 2006. Determination of salvinorins and divinatorins in Salvia divinorum leaves by liquid chromatography/multistage mass spectrometry. Rapid Commun Mass Spectrom 20: 131-136.
35. Mendelson JE, Coyle JR, Lopez JC, et al,. 2011. Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial. Psychopharmacol 214: 933-939.
36. Meyer EG, Writer BW,. 2012. Salvia divinorum. Psychosomatics 53: 277-279.
37. Miller BL, Griffin OH III, Gibson CL, Key DN,. 2009. Trippin on Sally D: exploring predictors of Salvia divinorum experimentation. J Crim Jus 37: 396-403.
38. Morani AS, Kivell B, Prisinzano TE, Schenk S,. 2009. Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats. Pharmacol Biochem Behav 94: 244-249.
39. Nemeth CL, Paine TA, Rittiner JE, et al,. 2010. Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats. Psychopharmacology 210: 263-274.
40. Nyi PP, Lai EP, Lee DY, Biglete SA, Torrecer GI, Anderson IB,. 2010. Influence of age on Salvia divinorum use: results of an Internet survey. J Psychoactive Drugs 42: 385-392.
41. Ogata J, Uchiyama N, Kikura-Hanajiri R, Goda Y,. 2012. DNA sequence analyses of blended herbal products including synthetic cannabinoids as designer drugs. Forensic Sci Int doi: 10.1016/j.forsciint.2012.09.006.
42. Paulzen M, Grunder G,. 2008. Toxic psychosis after intake of hallucinogen salvinorin A. J Clin Psychiatry 69: 1501.
43. Perron BE, Ahmedani BK, Vaughn MG, Glass JE, Abdon A, Wu LT,. 2012. Use of Salvia divinorum in a nationally representative sample. Am J Drug Alcohol Abuse 38: 108-113.
44. Pichini S, Abanades S, Farré M, Pellegrini M, Marchei E, Pacifici R,. 2005. Quantification of the plant-derived hallucinogen salvinorin A in conventional and non-conventional biological fluids by gas chromatography/mass spectrometry after Salvia divinorum smoking. Rapid Commun Mass Spectrom 19: 1649-1656.
45. Potter DN, Damex-Werno D, Carlezon WA Jr, Cohen BM, Chartoff EH,. 2011. Repeated exposure to the kappa-opioid receptor agonist salvinorin A modulates extracellular signal regulated kinase and reward sensitivity. Biol Psychiatry 70: 744-753.
46. Przekop P, Lee T,. 2009. Persistent psychosis associated with Salvia divinorum use. Am J Psychiatry 166: 832.
47. Ranganathan M, Schnakenberg A, Skosnik PD, et al,. 2012. Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist salvinorin A in humans. Biol Psychiatry 72: 871-879.
48. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S,. 2002. Salvinorin A: a potent naturally occurring nonnitrogenous κ opioid selective agonist. Proc Natl Acad Sci U S A 99: 11934-11939.
49. Schmidt MS, Prisinzano TE, Tidgewell W, Harding W, Butelman ER, Kreek MJ, Murry DJ,. 2005a. Determination of salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization. J Chromatogr B 818: 221-225.
50. Schmidt MD, Schmidt MS, Butelman ER, et al,. 2005b. Pharmacokinetics of the plant derived κ-opioid hallucinogen salvinorin A in nonhuman primates. Synapse 58: 208-210.
51. Schmidt MM, Sharma A, Schifano F, Feinmann C,. 2011. "Legal highs" on the net-evaluation of UK-based websites, products and product information. Forensic Sci Int 206: 92-97.
52. Singh S,. 2007. Adolescent salvia substance abuse. Addiction 102: 823-824.
53. Sumnall HR, Measham F, Brandt SD, Cole JC,. 2012. Salvia divinorum use and phenomenology: results from on line survey. J Psychopharm 25: 1498-1507.
54. Teksin ZS, Lee IJ, Nemieboka NN, Othman AA, Upreti VV, Hassan HE,. 2009. Evaluation of the transport, in vitro metabolism and pharmacokinetics of salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm 72: 471-477.
55. Travis CR, Ray GA, Marlowe KF,. 2012. A report on nausea and vomiting with discontinuation of chronic use of Salvia divinorum. Case Rep Med 2012: 543747.
56. Tsujikawa K, Kuwayama K, Miyaguchi H, et al,. 2008. Determination of salvinorin A and salvinorin B in Salvia divinorum-related products circulated in Japan. Forensic Sci Int 180: 105-109.
57. Tsujikawa K, Kuwayama K, Miyaguchi H, Kanamori T, Iwata YT, Inoue H,. 2009. In vitro stability and metabolism of salvinorin A in rat plasma. Xenobiotica 39: 391-398.
58. Vohra R, Seefeld A, Cantrell FL, Clark RF,. 2011. Salvia divinorum: exposures reported to a statewide poison control system over 10 years. J Emerg Med 40: 643-650.
59. Willard MAB, McGuffin VL, Smith RW,. 2012. Forensic analysis of Salvia divinorum using multivariate statistical procedures. Part I: discrimination from related Salvia species. Anal Bioanal Chem 402: 833-842.
60. Wolowich WR, Perkins AM, Cienki JJ,. 2006. Analysis of the psychoactive terpenoid salvinorin A content in five Salvia divinorum herbal products. Pharmacotherapy 26: 1268-1272.
61. Wu L-T, Woody GE, Yang C, Li J-H, Blazer DG,. 2011. Recent national trends in Salvia divinorum use and substance-use disorders among recent and former Salvia divinorum users compared with nonusers. Subst Abuse Rehabil 2011: 53-68.
62. Zhang Y., Butelman ER, Schlussman SD, Ho A, Kreek MJ., 2005. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology 179: 551-558.